Pharmaceutical manufacturer Sanofi has advised that Australia faces limited availability of Soframycin ear- and eye-drops 8 ml, with the potential for the medication to be out of stock. The framycetin sulfate 5mg/ml preparation is an S4 prescription-only medicine.
A spokesman for Sanofi Australia and New Zealand said the company had proactively informed its customers in relation to this matter, to ensure that they were aware and could seek an alternative medication if required.
‘We are managing this situation through our wholesale channel. We expect additional stock to arrive in Australia from mid-December,’ the spokesman said.
The aminoglycoside antibacterial is used for infections of the eye or skin and lids, mainly conjunctivitis, blepharitis and styes, and is indicated for corneal abrasions, ulcers and burns and for prophylactic use after removal of foreign bodies.